ESTIMATION OF SOCIO-ECONOMIC BURDEN OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE FOR A 5-YEAR PERIOD: A REGIONAL ASPECT
- Authors: Orlova E.A.1, Umerova A.R.1,2, Dorfman I.P.1, Orlov M.A.1, Abdullaev M.A.1
-
Affiliations:
- Astrakhan State Medical University
- Territorial body of Federal State Surveillance Service in Healthcare for Astrakhan Region
- Issue: Vol 9, No 2 (2021)
- Pages: 130-138
- Section: Articles
- URL: https://ogarev-online.ru/2307-9266/article/view/111675
- DOI: https://doi.org/10.19163/2307-9266-2021-9-2-130-138
- ID: 111675
Cite item
Full Text
Abstract
The aim of the study was to estimate the economic damage by COPD, including direct medical and non-medical costs and indirect costs associated with premature deaths of working-age individuals.Materials and methods. First, estimation of the economic COPD burden in Astrakhan region (AR) was carried out using the clinical and economic analysis of the "cost of illness" (COI). Direct medical costs of inpatient, outpatient, ambulance and emergency medical care, as well as direct non-medical costs associated with the disability benefits payments, were taken into account. Indirect costs were defined as economic losses from undelivered products due to premature deaths of working-age individuals.Results. From 2015 to 2019, the economic COPD burden in AR amounted to 757.11 million rubles in total, which is equivalent to 0.03% of the gross regional product covering a five-year period of the study. Direct medical and non-medical costs totaled 178.02 million rubles. In the structure of direct medical expenses, expenses for inpatient, as well as ambulance and emergency medical care during the study period, increased by 92.5% and 45.5%, respectively. While the costs for the outpatient care decreased by 31.9%, the increase in direct non-medical costs associated with the disability benefits payments, increased by 5.1% (2019). Indirect losses amounted to 579.09 million rubles.Conclusion. The structure of the main damage is dominated by indirect losses in the economy associated with premature deaths of working-age individuals. In the structure of direct medical costs, inpatient care costs prevailed. These studies indicate the need to continue an advanced analysis of the economic burden of COPD, as well as to optimize the treatment and prevention of the exacerbations development of this disease.
Full Text
##article.viewOnOriginalSite##About the authors
E. A. Orlova
Astrakhan State Medical University
Email: eorlova56@mail.ru
121, Bakinskaya Str., Astrakhan, Russia, 414000
A. R. Umerova
Astrakhan State Medical University ; Territorial body of Federal State Surveillance Service in Healthcare for Astrakhan Region
Email: adelya_umerova@mail.ru
121, Bakinskaya Str., Astrakhan, Russia, 414000; 27, Kommunisticheskaya Str., Astrakhan, Russia 414040
I. P. Dorfman
Astrakhan State Medical University
Email: inna1977@inbox.ru
121, Bakinskaya Str., Astrakhan, Russia, 414000
M. A. Orlov
Astrakhan State Medical University
Email: orlovdoc56@gmail.com
121, Bakinskaya Str., Astrakhan, Russia, 414000
M. A. Abdullaev
Astrakhan State Medical University
Email: abdullaev-musalitdin@mail.ru
121, Bakinskaya Str., Astrakhan, Russia, 414000
References
- Iheanacho I., Zhang S., King D., Rizzo M., Ismaila A.S. Economic Burden of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review // Int J Chron Obstruct Pulmon Dis. - 2020. - Vol.15. - P.439-460. doi: 10.2147/COPD.S234942.
- Кузьмичев Б.Ю., Воронина Л.П., Тарасочкина Д.С., Полунина О.С., Прокофьева Т.В., Липницкая Е.А., Полунина Е. А. Гипергомоцистеинемия как фактор риска осложненного течения инфаркта миокарда на фоне хронической обструктивной болезни легких // Астраханский медицинский журнал. - 2019. - Т. 14, № 3. - С. 79-87. doi: 10.17021/2019.14.3.79.87
- Blanco I., Diego I., Bueno P., Fernández E., Casas-Maldonado F., Esquinas C., Soriano J.B., Miravitlles M. Geographical distribution of COPD prevalence in Europe, estimated by an inverse distance weighting interpolation technique // International journal of chronic obstructive pulmonary disease. - 2017. - Vol.13. - p.57-67. doi: 10.2147/COPD.S150853
- Chuchalin A.G., Khaltaev N., Antonov N.S., Galkin D.V., Manakov L.G., Antonini P., Murphy M., Solodovnikov A.G., Bousquet J., Pereira M.H., Demko I.V. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation // International journal of chronic obstructive pulmonary disease. - 2014. - Vol.9. - P.963-974. doi: 10.2147/COPD.S67283
- ВОЗ (Всемирная организация здравоохранения). 10 ведущих причин смерти в мире. 2019.. URL: https://www.who.int/ru/news-room/fact-sheets/detail/the-top-10-causes-of-death.
- Li X., Zhou Y., Chen S., Zheng J., Zhong N., Ran P. Early intervention with tiotropium in Chinese patients with GOLD stages I-II chronic obstructive pulmonary disease (Tie-COPD) study protocol for a multicentre, double-blinded, randomised, controlled trial // Br. Med. J. Open. - 2014. - Vol.4, No.2. - e003991. doi: 10.1136/bmjopen-2013-003991
- Srivastava K., Thakur D., Sharma S., Punekar Y.S. Systematic review of humanistic and economic burden of symptomatic chronic obstructive pulmonary disease // Pharmaco Economics. - 2015. - Vol.33, No.5. - P.467-488. DOI: 10. 1007/s40273-015-0252-4.
- Mannino D.M., Higuchi K., Yu T.C., Zhou H., Li Y., Tian H., Suh K. Economic burden of chronic obstructive pulmonary disease by presence of comorbidities // Chest. - 2015. - Vol.148. - P.138-50. doi: 10.1378/chest.14-2434.
- European Respiratory Society. Lung health in Europe: a better understanding of lung disease and respiratory care in Europe facts & figures. 2014.. URL: https:// www.ersnet.org/..
- Крысанов И.С. Анализ стоимости хронической обструктивной болезни лёгких в Российской Федерации // Качественная клиническая практика. - 2014. - № 2. - С. 51-57.
- Концевая А.В., Муканеева Д.К., Баланова Ю.А., Худяков М.Б., Драпкина О.М. Экономический ущерб от болезней органов дыхания и хронической обструктивной болезни легких в Российской Федерации в 2016 году // Пульмонология. - 2019. - Т. 29, №2. - С. 159-166. doi: 10.18093/0869-0189-2019-29-2-159-166.
- Ehteshami-Afshar S., FitzGerald J.M., Doyle-Waters M.M., Sadatsafavi M. The global economic burden of asthma and chronic obstructive pulmonary disease // Int J Tuberc Lung Dis. - 2016. - Vol.20, No.1. - P.11-23. doi: 10.5588/ijtld.15.0472.
- Anees Ur. Rehman, Ahmad Hassali M.A., Muhammad S.A., Shah S., Abbas S., Hyder Ali I.A.B., Salman A. The economic burden of chronic obstructive pulmonary disease (COPD) in the USA, Europe, and Asia: results from a systematic review of the literature // Expert Rev Pharmacoecon Outcomes Res. - 2020. - Vol.20, No.6. - P.661-672. doi: 10.1080/14737167.2020.1678385.
- Stafyla E., Geitona M., Kerenidi T., Economou A., Daniil Z., Gourgoulianis K.I. The annual direct costs of stable COPD in Greece // Int J Chron Obstruct Pulmon Dis. - 2018. - Vol.13. - P.309-315. doi: 10.2147/COPD.S148051.
- Viegi G., Maio S., Fasola S., Baldacci S. Global Burden of Chronic Respiratory Diseases // J Aerosol Med Pulm Drug Deliv. - 2020. - Vol.33, No.4. - P.171-177. doi: 10.1089/jamp.2019.1576.
- Dhamane A.D., Witt E.A., Su J. Associations between COPD severity and work productivity, health-related quality of life, and health care resource use: a cross-sectional analysis of national survey data // J Occup Environ Med. - 2016. - Vol.58, No.6. - P.191-197. doi: 10.1097/JOM.0000000000000735
- Vitacca M., Bianchi L., Bazza A., Clini E.M. Advanced COPD patients under home mechanical ventilation and/or long term oxygen therapy: italian healthcare costs // Monaldi Arch Chest Dis. - 2011. - Vol.75, No.4. - P.207-214. doi: 10.4081/monaldi.2011.208
- Punekar Y.S., Wurst K., Shukla A. Resource use and costs up to two years post diagnosis among newly diagnosed COPD patients in the UK primary care setting: a retrospective cohort study // COPD. - 2015. - Vol.12, No.3. - P.267-275. doi: 10.3109/15412555.2014.933953
- Guarascio A.J., Ray S.M., Finch C.K., Self T.H. The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clinicoecon // Outcomes Res. - 2013. - Vol.5. - P.235-245. doi: 10.2147/CEOR.S34321.
- Ford E.S., Murphy L.B., Khavjou O., Giles W.H., Holt J.B., Croft J.B. Total and state-specific medical and absenteeism costs of COPD among adults aged ≥ 18 years in the United States for 2010 and projections through 2020 // Chest. - 2015. - Vol.147, No.1. - P.31-45. doi: 10.1378/chest.14-0972.
- Trueman D., Woodcock F., Hancock E. Estimating the economic burden of respiratory illness in the UK. British Lung Foundation. 2017.. URL: https://www.blf.org.uk/policy/economic-burden..
- Foo J., Landis S.H., Maskell J., Oh Y.M., Van Der Molen T., Han M.K., Punekar Y. Continuing to Confront COPD International Patient Survey: economic impact of COPD in 12 countries // PLoS One. - 2016. - Vol.11, No.4. - e0152618. doi: 10.1371/journal. pone.0152618.
- Wacker M.E., Jörres R.A., Schulz H., Heinrich J., Karrasch S., Karch A., Koch A., Peters A., Leidl R., Vogelmeier C., Holle R.; COSYCONET-Consortium. Direct and indirect costs of COPD and its comorbidities: Results from the German COSYCONET study // Respir Med. - 2016. - Vol.111. - P.39-46. doi: 10.1016/j.rmed.2015.12.001.
- Patel J.G., Nagar S.P., Dalal A.A. Indirect costs in chronic obstructive pulmonary disease: a review of the economic burden on employers and individuals in the United States // Int J Chron Obstruct Pulmon Dis. - 2014. - Vol.9. - P.289-300. doi: 10.2147/COPD.S57157.
Supplementary files
